Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 7,040 Shares of Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40. Following the completion of the sale, the chief executive officer owned 43,720 shares of the company’s stock, valued at approximately $2,271,691.20. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total value of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total value of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total value of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.12, for a total transaction of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.55, for a total transaction of $50,079.25.
• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total value of $552,372.84.

Phibro Animal Health Trading Down 2.3%

NASDAQ PAHC opened at $51.08 on Thursday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The stock has a market cap of $2.07 billion, a P/E ratio of 22.70, a price-to-earnings-growth ratio of 0.80 and a beta of 0.80. The stock has a 50 day simple moving average of $41.97 and a two-hundred day simple moving average of $39.69. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $56.30.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. The business had revenue of $373.91 million for the quarter, compared to analysts’ expectations of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend is Wednesday, March 4th. Phibro Animal Health’s payout ratio is presently 21.33%.

Institutional Investors Weigh In On Phibro Animal Health

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Phibro Animal Health by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock valued at $57,519,000 after purchasing an additional 13,884 shares during the last quarter. State Street Corp raised its position in Phibro Animal Health by 5.4% in the 4th quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after buying an additional 48,243 shares during the last quarter. Millennium Management LLC lifted its stake in Phibro Animal Health by 4,227.1% during the 4th quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after acquiring an additional 626,492 shares during the period. Geode Capital Management LLC lifted its stake in Phibro Animal Health by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock valued at $21,265,000 after acquiring an additional 21,951 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Phibro Animal Health by 1.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 492,335 shares of the company’s stock valued at $18,394,000 after acquiring an additional 6,826 shares during the last quarter. Institutional investors own 99.34% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. JPMorgan Chase & Co. raised their price objective on Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a research report on Friday, February 6th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $37.50.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.